Alogliptin (SYR-322) drug is considered to be a member of the DPP-4 inhibitors class, which are newer oral agents for the treating diabetes (type 2 diabetes). The drug was discovered by Takeda’s wholly owned subsidiary, Takeda San Diego, Inc. By the way, Takeda is also the author of the thiazolidinedione (TZD) diabetes medication. The aim [...]
It is known that such disease as type 2 diabetes is associated with a two- to four-fold increase in cardiovascular disease and also other cardiovascular risk factors, for example, cholesterol disorders and high blood pressure. Moreover, the main cause of mortality and morbidity for patients with type 2 diabetes is heart disease.
Actos (Pioglitazone) diabetes medication was introduced in August 1999. Since that time for the past 10 years there were conducted studies that have shown no proof that ACTOS drug is associated with an increase in risk of heart attack or stroke. As Pharmacoepidemiology and Drug Safety reported, nearly 30,000 patients were included in an observational [...]
Today were presented the new findings in a late-breaker session at the World Congress of Cardiology in Barcelona. An oral antidiabetic medication ACTOS (pioglitazone HCl) was investigated and it was revealed that Actos drug significantly reduced the risk of recurrent stroke in high-risk patients with type 2 diabetes. Nowadays patients with diabetes are at an [...]
